Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine

(2021) Daryl Hodge et al.   CLINICAL PHARMACOKINETICS

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

(2021) Shahin Lockman et al.   LANCET

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

(2021) Susan E. Dorman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overview of SARS-CoV-2 infection in adults living with HIV

(2021) Juan Ambrosioni et al.   Lancet HIV

No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

(2021) Andrew Atkinson et al.   Journal of the International AIDS Society

Recently acquired and early chronic hepatitis C in men having sex with men (MSM)

(2020) Christoph Boesecke   AIDS

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

(2020) L Ryom et al.   HIV MEDICINE

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

(2020) Edgar T Overton et al.   LANCET

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETOLOGIA